Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients

Aksamit, Timothy R.; Locantore, Nicholas; Addrizzo-Harris, Doreen; Ali, Juzar; Barker, Alan; Basavaraj, Ashwin; Behrman, Megan; Brunton, Amanda E.; Chalmers, Sarah; Choate, Radmila; Dean, Nathan C.; DiMango, Angela; Fraulino, David; Johnson, Margaret M.; Lapinel, Nicole C.; Maselli, Diego J.; McShane, Pamela J.; Metersky, Mark L.; Miller, Bruce E.; Naureckas, Edward T.; O’Donnell, Anne E.; Olivier, Kenneth N.; Prusinowski, Elly; Restrepo, Marcos I.; Richards, Christopher J.; Rhyne, Gloria; Schmid, Andreas; Solomon, George M.; Tal-Singer, Ruth; Thomashow, Byron; Tino, Gregory; Tsui, Kevin; Varghese, Sumith Abraham; Warren, Heather E.; Winthrop, Kevin; Zha, Beth Shoshanna

doi:10.1164/rccm.202307-1165oc

Cited by 2 publications

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical Predictors of Nontuberculous Mycobacteria Lung Disease and Coisolates of Potential Pathogenic Microorganisms in Noncystic Fibrosis Bronchiectasis

Wang,

Shu,

Sheu

et al. 2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background In bronchiectasis, non-tuberculous mycobacteria (NTM) lung disease (NTM-LD) is a well-known coexisting infection. However, microorganism co-isolates and clinical NTM-LD predictors are poorly studied. Methods Patients diagnosed with bronchiectasis by computed tomography between January 2017 and June 2020 were screened, using the computed tomography’s date as the index date. Those with a major bronchiectasis diagnosis in at least two follow-ups after the index date were enrolled in the study, and NTM-LD occurrence and its association with pneumonia and hospitalization within one year were analyzed. Results Of the 2717 participants, 79 (2.9%) were diagnosed with NTM-LD. The factors associated with NTM-LD included hemoptysis, post-infectious bronchiectasis, a tree-in-bud score ≥2, a modified Reiff score of ≥4, and COPD (adjusted odds ratios: 1.80, 2.36, 1.78, 2.95, and 0.51, respectively. Compared with those with non-NTM, patients with NTM-LD had higher hospitalization (15.9% vs. 32.9%, p < 0.001) and pneumonia (9.8% vs. 20.3%, p = 0.003) rates. Pseudomonas aeruginosa was the most common microorganism in those with NTM-LD and non-NTM (10.1% vs. 7.8%, p = 0.40). However, when compared with those with non-NTM, Acinetobacter baumannii and Escherichia coli were more prevalent in patients with NTM-LD (0.7% vs. 3.8%, p = 0.027 and 1.0% vs. 3.8%, p = 0.05, respectively). Conclusions Post-infectious bronchiectasis with hemoptysis, higher radiological involvement, and a tree-in-bud pattern were associated with NTM-LD risk. The rate of Acinetobacter baumannii and Escherichia coli co-isolation was higher in bronchiectasis populations with NTM-LD.

show abstract

Clinical Predictors of Nontuberculous Mycobacteria Lung Disease and Coisolates of Potential Pathogenic Microorganisms in Noncystic Fibrosis Bronchiectasis

Wang,

Shu,

Sheu

et al. 2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

Epidemiology of non-cystic fibrosis bronchiectasis at a single center in Japan: a retrospective cohort study

Hashimoto,

Abe,

Fukushima

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: The characteristics of non-cystic fibrosis bronchiectasis (NCBE) in Asia, including Japan, remain largely unknown. We aimed to provide insights into the clinical characteristics and treatment outcomes of NCBE, especially regarding nontuberculous mycobacteria (NTM) infection, and establish a basis for comparison with global datasets. In addition, long-term macrolide antibiotic use in patients with NCBE and a history of exacerbations is established, but the effects in patients without exacerbations remain unclear. Methods: In this single-center, retrospective study, the medical records of patients who satisfied the NCBE criteria between 1 January 2012 and 31 August 2023 were reviewed. Severe exacerbations and mortality during the observation period were recorded. Baseline characteristics, prognostic factors, and overall survival of patients with and without non-NTM infection were evaluated; effects of long-term macrolide antibiotic use in patients without severe exacerbations were estimated using inverse probability weighting (IPW). Results: In 1044 patients with bronchiectasis, severe exacerbation rates were 22·32%, with mortality rates of 3·16% at 3 years. Notably, the high prevalence of NTM infection (n=458, 43·87%) in this cohort was distinctive. Compared with the NTM group, the non-NTM group had a higher proportion of elevated inflammatory markers, with significant differences in C-reactive protein levels (p=0·0023) and blood neutrophil counts (p<0·001). Pseudomonas aeruginosa was more frequently identified as having colonization and was associated with severe exacerbations (p<0·001) in the non-NTM group. NTM infection was not associated with mortality (p=0·4621, hazard ratio=0·79). Among patients with non-NTM infection and without a history of exacerbation in the past 2 years, 34·3% received long-term macrolide antibiotics that did not invariably reduce severe exacerbations (P=0·3801, IPW P=0·7222). Conclusions: This study highlights NCBE epidemiology in Japan, advising caution in the casual use of macrolides for mild cases. Clinical Trial Registration: UMIN Clinical Trials Registry Number: UMIN000054726 (Registered on 21 June 2024)

show abstract

Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients

Cited by 2 publications

References 50 publications

Clinical Predictors of Nontuberculous Mycobacteria Lung Disease and Coisolates of Potential Pathogenic Microorganisms in Noncystic Fibrosis Bronchiectasis

Clinical Predictors of Nontuberculous Mycobacteria Lung Disease and Coisolates of Potential Pathogenic Microorganisms in Noncystic Fibrosis Bronchiectasis

Epidemiology of non-cystic fibrosis bronchiectasis at a single center in Japan: a retrospective cohort study

Contact Info

Product

Resources

About